Deal Lilly deal · amount not disclosed · announced Jan 29, 2026 Company release ↗Source quote
Jan 29, 2026 · Company release ↗ “Collaboration unites Repertoire’s DECODE ™ platform to develop T cell targeted immune medicines with Lilly’s commitment to bringing transformative medicines to patients with unmet need CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines,”
Trial start T: An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors source ↗
Trial start Phase 1: RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma source ↗
Trial start —: This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Pr source ↗
Trial start Phase 1: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas source ↗
Upcoming milestones
Dec 15, 2028 (ESTIMATED) · T · An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · NCT07293754
Estimated primary completion per ClinicalTrials.gov. Dates move.
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
